Fulcrum Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Positive phase I-B data for pociredir in sickle cell disease showed robust HbF increases and reduced VOCs, with strong safety and a solid cash runway into 2029. A registration-enabling trial is planned for the second half of 2026, pending FDA feedback.
-
PIONEER study data showed strong HbF induction, VOC reduction, and a favorable safety profile, generating positive feedback and interest for future trials. The next step is a pivotal registrational study with interim analysis for accelerated approval, while business focus remains on sickle cell disease and U.S. commercialization.
-
Pociredir, an oral fetal hemoglobin inducer, showed robust HbF increases and improved clinical markers in sickle cell patients, with over half reaching transformative HbF levels and a strong safety profile. A registrational phase 3 study and open-label extension are planned for 2024.
Fiscal Year 2025
-
The 20-mg cohort in the PIONEER trial showed robust HbF induction, improved anemia and hemolysis, and encouraging VOC reduction, with pociredir well-tolerated and poised for late-stage trials. Plans are underway for global expansion and regulatory engagement.
-
The 20 mg dose of pociredir demonstrated robust and rapid increases in fetal hemoglobin, significant reductions in anemia and hemolysis, and encouraging trends in reducing VOCs, with a strong safety profile. Plans are in place for regulatory engagement, an open-label extension, and a registrational study.
-
Lead program pociredir showed strong Phase I-B results in sickle cell disease, with robust increases in fetal hemoglobin and favorable safety. Cash reserves of $200.6M are expected to fund operations into 2028, supporting ongoing clinical and preclinical programs.
-
A novel oral therapy for sickle cell disease demonstrated robust increases in fetal hemoglobin, significant reductions in pain crises, and a strong safety profile in early clinical data. Next steps include higher-dose cohort results by year-end and potential advancement to registrational studies.
-
The conference highlighted strong phase 1B data for an oral sickle cell therapy, showing robust HbF induction, significant VOC reduction, and a favorable safety profile in severe patients. Upcoming 20 mg data and regulatory discussions could broaden market potential.
-
Pociredir, a PRC2 inhibitor, is advancing in Phase 1b trials for severe sickle cell disease, with key data readouts expected in Q3 and year-end 2024. The company is well-funded, expanding its pipeline into other rare hematological diseases, and aims for regulatory discussions on broader patient access and accelerated approval pathways.
-
Focused on rare hematological diseases, the company’s lead asset, Pociredir, targets sickle cell disease by inducing fetal hemoglobin and is in phase 1B trials. Recent setbacks in competing therapies highlight a high unmet need, and robust upcoming data could expand patient eligibility.
-
Enrollment completed for the 12 mg cohort in the Pociredir phase 1b trial, with strong adherence and no discontinuations; financials show reduced expenses and improved net loss year-over-year. Cash runway extends into 2027, with key data readouts expected in 2025.
-
Two key Phase 1b readouts for pociredir in sickle cell disease are expected in 2025, focusing on safety and fetal hemoglobin increases. Enrollment is strong, and the study targets severe patients. Regulatory discussions may enable broader criteria and shorter pivotal studies if data are positive.
-
Pociredir is advancing in sickle cell disease, with mid-year and year-end data expected for key cohorts. Improved patient adherence and regulatory engagement on surrogate endpoints are underway. The pipeline includes a new oral agent for Diamond-Blackfan anemia, with IND submission targeted for Q4.
Fiscal Year 2024
-
Pociredir advanced in sickle cell disease with key data readouts expected in 2025, while strong cash reserves and an $80M Sanofi payment support operations into 2027. Focus remains on benign hematology, with FSHD discontinued and new INDs planned.
-
Recent advances in sickle cell disease have not met broad patient needs, prompting renewed focus on fetal hemoglobin. Pociredir, an oral PRC2 inhibitor, shows promise in raising fetal hemoglobin and is advancing through a refined clinical trial with data expected in 2025.
-
Focus has shifted to oral therapies for rare benign hematology, with pociredir in Phase Ib for sickle cell disease. Enrollment is progressing, with key data from the 12 mg cohort expected in early 2025 and regulatory strategies targeting both risk-benefit and surrogate endpoints.
-
Suspension of losmapimod and a 40% workforce reduction refocused efforts on pociredir for sickle cell disease, with strong cash reserves of $257.2 million and a robust preclinical pipeline. Pociredir's phase I-B trial is progressing, with data expected in 2025 and funding secured into 2027.
-
Q2 2024 saw a strong financial boost from an $80M Sanofi payment, driving net income and cash reserves higher. Losmapimod's phase III REACH trial is on track for top-line data by October, with high patient retention and commercial launch preparations underway.
-
Upcoming phase III data for losmapimod in FSHD could deliver the first approved therapy for this disease, with a robust trial design and strong regulatory engagement. A major Sanofi partnership supports global commercialization, and the pipeline includes promising sickle cell therapy pociredir.